Investment ThemesDetailed Quotes
Gene Editing
Watchlist
Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1441.420
- -3.955-0.27%
Close Feb 26 16:00 ET
1461.453High1430.968Low
1442.167Open1445.375Pre Close15.84MVolume3RiseLossP/E (Static)775.92MTurnover--Flatline1.27%Turnover Ratio172.41BMarket Cap7Fall170.19BFloat Cap
Constituent Stocks: 10Top Rising: SGMO+2.41%
Insiders loading up! Is there something big coming?🤔
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
Friday, 21st February at 7:30 am
bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions
bluebird's Board of Directors determined this transaction is in the best interest of stockholders following a comprehensive review of strategic alternatives
...
Can bluebird bio Hit $600M Sales Target? What the $9.84 Per Share Buyout Really Means
Bluebird bio Announces Definitive Agreement to Be Acquired by Carlyle and SK Capital! Bluebird bio Inc - Stockholders to Receive $3.00 per Share in Cash
Bluebird Bio: Contingent Value Right of $6.84/Share Payable Upon Achievement of Sales Milestone
The transaction is expected to close in the first half of 2025, subject to the tender of a majority of the outstandin...
No comment yet